

Figure 1


Competitive inhibition of ¹⁰³³-trastuzumab

Figure 1: Competitive inhibition of ¹¹¹In labelled 1033-trastuzumab binding to SKBR-3 cells by cold (unlabelled, without 1033-conjugate) trastuzumab.

2/5

Figure 2




Figure 2: Comparison of whole body clearance of radioactivity in rats injected with ^{111}In -1033-trastuzumab (filled triangles) or ^{111}In -1033-rituximab (filled squares) antibody conjugates expressed as percentage \pm std.dev. The data are corrected for radioactivity decay and background.

3/5

Figure 3




Figure 3: Comparison of whole blood clearance of radioactivity in rats, injected with ^{111}In -1033-trastuzumab (filled triangles) or ^{111}In -1033-rituximab (filled squares) antibody conjugates, expressed as % of activity at start \pm std.dev. The data are corrected for radioactivity decay.

4/5

Figure 4




Figure 4: Biodistribution of ^{111}In -1033-trastuzumab in rats, expressed as % of injected dose per gram tissue \pm std.dev. The results are corrected for radiochemical decay.

5/5


Figure 5

Figure 5: Biodistribution of ^{111}In -1033-rituximab in rats, expressed as % of injected dose per gram tissue \pm std.dev. The results are corrected for radiochemical decay.